- Home
- APPS vs GOSS Comparison
APPS vs GOSS Comparison
Compare APPS & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APPS
- GOSS
- Stock Information
- Founded
- APPS N/A
- GOSS 2015
- Country
- APPS United States
- GOSS United States
- Employees
- APPS N/A
- GOSS N/A
- Industry
- APPS Multi-Sector Companies
- GOSS Biotechnology: Pharmaceutical Preparations
- Sector
- APPS Miscellaneous
- GOSS Health Care
- Exchange
- APPS Nasdaq
- GOSS Nasdaq
- Market Cap
- APPS 562.7M
- GOSS 501.2M
- IPO Year
- APPS N/A
- GOSS 2019
- Fundamental
- Price
- APPS $6.26
- GOSS $2.39
- Analyst Decision
- APPS Buy
- GOSS Strong Buy
- Analyst Count
- APPS 3
- GOSS 6
- Target Price
- APPS $4.83
- GOSS $8.60
- AVG Volume (30 Days)
- APPS 2.7M
- GOSS 3.2M
- Earning Date
- APPS 11-04-2025
- GOSS 11-03-2025
- Dividend Yield
- APPS N/A
- GOSS N/A
- EPS Growth
- APPS N/A
- GOSS N/A
- EPS
- APPS N/A
- GOSS N/A
- Revenue
- APPS $503,443,000.00
- GOSS $40,237,000.00
- Revenue This Year
- APPS $10.64
- GOSS N/A
- Revenue Next Year
- APPS $11.24
- GOSS $16.11
- P/E Ratio
- APPS N/A
- GOSS N/A
- Revenue Growth
- APPS N/A
- GOSS N/A
- 52 Week Low
- APPS $1.18
- GOSS $0.66
- 52 Week High
- APPS $7.77
- GOSS $3.60
- Technical
- Relative Strength Index (RSI)
- APPS 50.18
- GOSS 48.48
- Support Level
- APPS $6.07
- GOSS $2.28
- Resistance Level
- APPS $6.92
- GOSS $2.53
- Average True Range (ATR)
- APPS 0.45
- GOSS 0.16
- MACD
- APPS -0.10
- GOSS 0.01
- Stochastic Oscillator
- APPS 14.11
- GOSS 61.05
About APPS Digital Turbine Inc.
Digital Turbine Inc is an independent mobile growth platform. It offers end-to-end products and solutions to all participants in the mobile application ecosystem, enabling brand discovery and advertising, user acquisition and engagement, and operational efficiency for advertisers. Its operating segments are On Device Solutions and App Growth Platform.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.